Diplomat Pharmacy Inc (NYSE:DPLO) – William Blair decreased their FY2019 EPS estimates for shares of Diplomat Pharmacy in a research note issued to investors on Tuesday, November 12th. William Blair analyst J. Kreger now expects that the company will post earnings per share of ($0.95) for the year, down from their previous estimate of ($0.80). William Blair also issued estimates for Diplomat Pharmacy’s Q4 2019 earnings at ($0.22) EPS, FY2020 earnings at ($0.82) EPS, FY2021 earnings at ($0.75) EPS, FY2022 earnings at ($0.68) EPS and FY2023 earnings at ($0.63) EPS.
Several other equities analysts have also recently issued reports on the company. Barclays cut Diplomat Pharmacy from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $7.00 to $3.00 in a research report on Wednesday. Deutsche Bank began coverage on Diplomat Pharmacy in a research note on Thursday, September 12th. They set a “sell” rating and a $4.00 price objective for the company. Wells Fargo & Co raised their price objective on Diplomat Pharmacy from $5.00 to $5.50 and gave the stock a “market perform” rating in a research note on Tuesday, August 13th. ValuEngine lowered Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Wednesday. Finally, Zacks Investment Research raised Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Monday, October 14th. Three equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $9.14.
Shares of DPLO stock traded up $0.13 during mid-day trading on Friday, hitting $3.47. 46,209 shares of the stock traded hands, compared to its average volume of 1,311,251. Diplomat Pharmacy has a twelve month low of $2.43 and a twelve month high of $16.35. The firm has a market cap of $253.27 million, a price-to-earnings ratio of 17.50 and a beta of 1.00. The company’s 50-day simple moving average is $5.10 and its 200-day simple moving average is $5.36. The company has a debt-to-equity ratio of 0.18, a quick ratio of 0.66 and a current ratio of 0.55.
Diplomat Pharmacy (NYSE:DPLO) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($2.35) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($2.15). Diplomat Pharmacy had a negative net margin of 12.47% and a negative return on equity of 12.15%. The firm had revenue of $1.30 billion for the quarter, compared to analyst estimates of $1.17 billion. The company’s revenue was down 5.3% on a year-over-year basis.
Institutional investors have recently modified their holdings of the company. BlackRock Inc. boosted its stake in Diplomat Pharmacy by 7.2% in the second quarter. BlackRock Inc. now owns 9,154,249 shares of the company’s stock valued at $55,749,000 after acquiring an additional 614,918 shares during the last quarter. Stephens Inc. AR increased its holdings in shares of Diplomat Pharmacy by 1,482.3% in the 2nd quarter. Stephens Inc. AR now owns 6,600,015 shares of the company’s stock worth $40,194,000 after buying an additional 6,182,889 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Diplomat Pharmacy by 3.4% in the 2nd quarter. Vanguard Group Inc. now owns 5,708,105 shares of the company’s stock worth $34,764,000 after buying an additional 185,431 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Diplomat Pharmacy by 390.0% in the 2nd quarter. JPMorgan Chase & Co. now owns 1,445,834 shares of the company’s stock worth $8,632,000 after buying an additional 1,150,740 shares during the last quarter. Finally, Northern Trust Corp increased its holdings in shares of Diplomat Pharmacy by 0.9% in the 2nd quarter. Northern Trust Corp now owns 1,287,550 shares of the company’s stock worth $7,842,000 after buying an additional 11,656 shares during the last quarter. 84.35% of the stock is owned by institutional investors and hedge funds.
About Diplomat Pharmacy
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Featured Article: Book Value Per Share – BVPS
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.